

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# FOSUN PHARMA 复星医药

上海復星醫藥(集團)股份有限公司  
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

(a a a P R b C a ab )  
(Stock Code: 02196)

## 2021 FIRST QUARTERLY REPORT

Company

Group

2021 First Quarterly Report

Reporting Period

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Wu Yifang

Chairman

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

\* for identification purposes only

## 1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) are responsible for the management and supervision of the company's business operations and financial activities, respectively. The Board is composed of the Chairman, the President, and the Directors, while the Supervisory Committee is composed of the Chairman and the Supervisors. The Board and the Supervisory Committee are required to exercise their duties in a fair and equitable manner, and to act in the best interests of the company and its shareholders.
2. The Board and the Supervisory Committee are required to disclose any material information that may affect the company's financial position or business operations to the shareholders and the public. This includes information regarding the company's financial performance, business strategy, and any significant risks or uncertainties that may affect the company's future prospects.
3. The Board and the Supervisory Committee are required to ensure that the company's financial statements are prepared in accordance with the applicable accounting standards and are audited by an independent auditor. The Board is also responsible for the company's internal control system and for ensuring that the company's financial reporting is accurate and reliable.
4. The Board and the Supervisory Committee are required to comply with all applicable laws and regulations, and to act in a manner that is consistent with the company's mission and values. The Board and the Supervisory Committee are also required to maintain the highest standards of integrity and ethical conduct in all of their actions.



1. The following information is available for the year ended 31/12/2021:

Accounting period: 1/1/2021 to 31/3/2021

Items	Jan - Mar 2021
Revenue	1000000
Cost of sales (1000000 x 0.75)	750000
Profit before tax	250000
Income tax expense	100000
Profit after tax	150000
Dividends paid	100000
Retained profit	50000

2. The following information is available for the year ended 31/12/2021:

Accounting period



### 3. SIGNIFICANT EVENTS

▲ 7. 2019年12月31日，公司资产总额为1,000,000,000.00元，较2018年12月31日增加100,000,000.00元，增幅为10%。

(一) 资产

2019年12月31日

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
货币资金	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司货币资金余额较期初增加100,000,000.00元，增幅为10%。
应收账款	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司应收账款余额较期初增加100,000,000.00元，增幅为10%。
预付款项	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司预付款项余额较期初增加100,000,000.00元，增幅为10%。
其他应收款	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司其他应收款余额较期初增加100,000,000.00元，增幅为10%。
流动资产合计	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司流动资产合计较期初增加100,000,000.00元，增幅为10%。
非流动资产	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司非流动资产较期初增加100,000,000.00元，增幅为10%。
总资产	1,000,000,000.00	1,000,000,000.00	100.00%	报告期内，公司总资产较期初增加100,000,000.00元，增幅为10%。

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan - Mar 2021	Jan - Mar 2020		
Revenue	11,111,111.11	11,111,111.11	100.00%	Revenue increased due to the expansion of the business scope and the increase in the number of customers.
Cost of sales	6,666,666.67	6,666,666.67	100.00%	Cost of sales increased due to the increase in the volume of sales and the increase in the price of raw materials.
Operating expenses	2,222,222.22	2,222,222.22	100.00%	Operating expenses increased due to the increase in the number of employees and the increase in the price of office supplies.
Operating income	2,222,222.22	2,222,222.22	100.00%	Operating income increased due to the increase in the volume of sales and the decrease in the cost of sales.
Other income	1,111,111.11	1,111,111.11	100.00%	Other income increased due to the increase in the number of interest income and the increase in the price of securities.
Other expenses	1,111,111.11	1,111,111.11	100.00%	Other expenses increased due to the increase in the number of interest expense and the increase in the price of securities.
Income before income tax	3,333,333.33	3,333,333.33	100.00%	Income before income tax increased due to the increase in the volume of sales and the decrease in the cost of sales.
Income tax expense	1,111,111.11	1,111,111.11	100.00%	Income tax expense increased due to the increase in the volume of sales and the increase in the tax rate.
Net income	2,222,222.22	2,222,222.22	100.00%	Net income increased due to the increase in the volume of sales and the decrease in the cost of sales.

( )



... 7% ... %

1- ...

... (Non-public Offering) ...

... CSRC (《中國證監會行政許可申請受理單》) ...

... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

... ( ) ...

2- ...

... 21 Fosun Pharma 01 ... %

... 2021年12月31日 ... %

... ( ) ...  
( 16 Fosun Pharma 01 )-

...

... ( ) ( 2021 Restricted Share Incentive Scheme )

... %  
... ( )- ... %  
... %  
... %

...

...

...

...

...

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

... Wu Yifang

...

\* for identification purposes only

## 4. APPENDICES

### 4.1 Financial statements

#### Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses	123,456,789	112,345,678
Other receivables	98,765,432	87,654,321
Inventory	567,890,123	545,678,901
Other current assets	345,678,901	323,456,789
<b>Non-current assets:</b>		
Property, plant and equipment	1,234,567,890	1,123,456,789
Intangible assets	876,543,210	765,432,109
Investments in subsidiaries	654,321,098	543,210,987
Investments in associates	432,109,876	321,098,765
Other non-current assets	210,987,654	109,876,543
<b>Total assets</b>	<b>5,139,286,876</b>	<b>4,851,934,567</b>
<b>Current liabilities:</b>		
Accounts payable	345,678,901	323,456,789
Other payables	234,567,890	212,345,678
Short-term borrowings	123,456,789	112,345,678
Other current liabilities	98,765,432	87,654,321
<b>Non-current liabilities:</b>		
Long-term borrowings	567,890,123	545,678,901
Other non-current liabilities	345,678,901	323,456,789
<b>Total liabilities</b>	<b>1,317,377,934</b>	<b>1,292,337,476</b>
<b>Equity</b>	<b>3,821,908,942</b>	<b>3,559,597,091</b>
Capital	1,234,567,890	1,123,456,789
Reserves	2,587,341,052	2,436,140,302



## Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	31 March 2021	31 December 2020
<b>Current assets:</b>		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses and other receivables	123,456,789	112,345,678
Inventory	345,678,901	323,456,789
Other current assets	456,789,012	434,567,890
<b>Non-current assets:</b>		
Property, plant and equipment	567,890,123	545,678,901
Intangible assets	678,901,234	656,789,012
Long-term equity investments	789,012,345	767,890,123
Other non-current assets	890,123,456	868,901,234
<b>Current liabilities:</b>		
Accounts payable	901,234,567	879,012,345
Short-term debt	1,012,345,678	990,123,456
Other current liabilities	1,123,456,789	1,098,765,432
<b>Non-current liabilities:</b>		
Long-term debt	1,234,567,890	1,212,345,678
Other non-current liabilities	1,345,678,901	1,323,456,789

## Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
<b>Non-current liabilities:</b>		
Long-term debt	1,234,567.89	1,123,456.78
Deferred income tax	123,456.78	134,567.89
Other non-current liabilities	567,890.12	678,901.23
Total non-current liabilities	1,925,914.79	1,936,925.90
<b>Equity:</b>		
Share capital	1,000,000.00	1,000,000.00
Reserves	800,000.00	750,000.00
Other equity	125,914.79	236,925.90
Total equity	1,925,914.79	1,986,925.90

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**

## Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
I - 营业收入 (营业收入)	117,250,111.14	111,111,111.11
II - 营业成本 (营业成本)	22,111,111.11	22,111,111.11
III - 营业税金及附加 (营业税金及附加)	1,111,111.11	1,111,111.11
IV - 销售费用 (销售费用)	11,111,111.11	11,111,111.11
V - 管理费用 (管理费用)	11,111,111.11	11,111,111.11
VI - 研发费用 (研发费用)	11,111,111.11	11,111,111.11
VII - 财务费用 (财务费用)	1,111,111.11	1,111,111.11
VIII - 资产减值损失 (资产减值损失)	1,111,111.11	1,111,111.11
IX - 公允价值变动收益 (公允价值变动收益)	1,111,111.11	1,111,111.11
X - 其他收益 (其他收益)	1,111,111.11	1,111,111.11
XI - 营业外收入 (营业外收入)	1,111,111.11	1,111,111.11
XII - 营业外支出 (营业外支出)	1,111,111.11	1,111,111.11
XIII - 所得税费用 (所得税费用)	1,111,111.11	1,111,111.11
XIV - 少数股东损益 (少数股东损益)	1,111,111.11	1,111,111.11
XV - 归属于母公司所有者的净利润 (归属于母公司所有者的净利润)	11,111,111.11	11,111,111.11
XVI - 归属于少数股东的净利润 (归属于少数股东的净利润)	1,111,111.11	1,111,111.11
XVII - 归属于母公司所有者的其他综合收益 (归属于母公司所有者的其他综合收益)	1,111,111.11	1,111,111.11
XVIII - 归属于少数股东的其他综合收益 (归属于少数股东的其他综合收益)	1,111,111.11	1,111,111.11
XIX - 归属于母公司所有者的综合收益总额 (归属于母公司所有者的综合收益总额)	11,111,111.11	11,111,111.11
XX - 归属于少数股东的综合收益总额 (归属于少数股东的综合收益总额)	1,111,111.11	1,111,111.11

## Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,111,111.11	1,111,111.11
二、营业成本	(666,666.67)	(666,666.67)
(一) 营业成本	(666,666.67)	(666,666.67)
三、营业利润	444,444.44	444,444.44
四、营业外收入	111,111.11	111,111.11
五、营业外支出	(111,111.11)	(111,111.11)
六、利润总额	444,444.44	444,444.44
七、所得税费用	(111,111.11)	(111,111.11)
八、净利润	333,333.33	333,333.33
(一) 净利润	333,333.33	333,333.33
(二) 少数股东损益	-	-
九、其他综合收益	-	-
十、综合收益总额	333,333.33	333,333.33
(一) 综合收益总额	333,333.33	333,333.33
(二) 少数股东损益	-	-

*Legal Representative:*  
**Wu Yifang**

*Chief Financial Officer:*  
**Guan Xiaohui**

*Director of the Accounting Department:*  
**Yan Jia**





**Income Statement of the Parent Company (Continued)**

*January – March 2021*

Items	Jan – Mar 2021	Jan – Mar 2020
( )		
( )		

*Legal Representative:*

**Wu Yifang**

*Chief Financial Officer:*

**Guan Xiaohui**

*Director of the Accounting Department:*

**Yan Jia**





## Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

Items	Jan – Mar 2021	Jan – Mar 2020
<b>I. Cash flow generated from operating activities:</b>		
Net income	1,111,111	1,111,111
Depreciation and amortization	2,222,222	2,222,222
Provision for doubtful accounts	3,333,333	3,333,333
Change in accounts receivable	4,444,444	4,444,444
Change in accounts payable	5,555,555	5,555,555
Change in prepayments	6,666,666	6,666,666
Change in other receivables	7,777,777	7,777,777
Change in other payables	8,888,888	8,888,888
Change in deferred income	9,999,999	9,999,999
Change in other non-current assets	10,101,010	10,101,010
Change in other non-current liabilities	11,111,111	11,111,111
Change in cash and cash equivalents	12,121,212	12,121,212
<b>II. Cash flow generated from investing activities:</b>		
Capital expenditures	13,131,313	13,131,313
Acquisition of intangible assets	14,141,414	14,141,414
Disposal of fixed assets	15,151,515	15,151,515
Disposal of intangible assets	16,161,616	16,161,616
Disposal of other non-current assets	17,171,717	17,171,717
Disposal of other non-current liabilities	18,181,818	18,181,818
Change in cash and cash equivalents	19,191,919	19,191,919
Change in cash and cash equivalents	20,202,020	20,202,020

